Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief R&D Strategy Officer | November 16, 2022 | November 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date November 16, 2022 · Filed November 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,878 |
Reported balance
After 2022-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-16 · Exercise / conversion · Acquired 13,767 · Balance 80,878 F1: Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 90,604 |
Reported balance
After 2022-11-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-16 · Exercise / conversion · Acquired 9,726 · Balance 90,604 |
| Common StockSEC Table I · non-derivative | Direct | 96,603 |
Reported balance
After 2022-11-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2022-11-16 · Exercise / conversion · Acquired 5,999 · Balance 96,603 |
| Common StockSEC Table I · non-derivative | Direct | 132,259 |
Reported balance
After 2022-11-16 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2022-11-16 · Exercise / conversion · Acquired 35,656 · Balance 132,259 |
| Common StockSEC Table I · non-derivative | Direct | 167,590 |
Reported balance
After 2022-11-16 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2022-11-16 · Exercise / conversion · Acquired 35,331 · Balance 167,590 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2023-09-26 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-16 · Exercise / conversion · Disposed 13,767 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2024-10-22 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-16 · Exercise / conversion · Disposed 9,726 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2025-03-26 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-16 · Exercise / conversion · Disposed 5,999 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2025-10-28 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-16 · Exercise / conversion · Disposed 35,656 · Balance 0 F2: The stock option is vested in full. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2026-04-29 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-16 · Exercise / conversion · Disposed 35,331 · Balance 0 F2: The stock option is vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
F2: The stock option is vested in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 35,331 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · derivative · entry 10 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,331 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 35,656 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · derivative · entry 9 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,656 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,999 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · derivative · entry 8 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,999 shares Expires 2025-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 9,726 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · derivative · entry 7 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,726 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 13,767 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · derivative · entry 6 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,767 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 35,331 | $4.21 | $148,743.51 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · nonDerivative · entry 5 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 35,656 | $1.16 | $41,360.96 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · nonDerivative · entry 4 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,999 | $1.89 | $11,338.11 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · nonDerivative · entry 3 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 9,726 | $1.89 | $18,382.14 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 23:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 13,767 | $0.87 | $11,977.29 |
DisclosureSEC source: 0001104659-22-119974 · tm2230775-3_4seq1.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief R&D Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:38 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 2,119 | $24.28 | $51,449.32 |
DisclosureSEC source: 0001104659-22-029519 · tm228264-1_4seq1.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,538 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 6,125 vested restricted stock units on February 28, 2022. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $28.73 | $0.00 |
DisclosureSEC source: 0001104659-22-024840 · tm227111-3_4seq1.xml · derivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-02-14 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:25 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-024840 · tm227111-3_4seq1.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,657 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. F2 · balance_after: Includes an aggregate of 403 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2021. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:49 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001104659-21-107818 · tm2125489-1_4seq1.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,767 Underlying: Common Stock · 10,000 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is vested in full. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:49 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 14,779 | $47.56 | $702,889.24 |
DisclosureSEC source: 0001104659-21-107818 · tm2125489-1_4seq1.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,254 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 7, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.10 to $48.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F1 · balance_after: Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:49 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 10,000 | $0.87 | $8,700.00 |
DisclosureSEC source: 0001104659-21-107818 · tm2125489-1_4seq1.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 606 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $23.57 | $0.00 |
DisclosureSEC source: 0001209191-21-014976 · doc4.xml · derivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014976 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,427 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. F2 · balance_after: Includes an aggregate of 2,625 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2019 and March 9, 2020. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 22:46 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-014092 · doc4.xml · derivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| August 06, 2019 Filed Aug 8, 2019 22:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,395 | $8.85 | $30,044.05 |
DisclosureSEC source: 0001209191-19-045196 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,802 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.2255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 8, 2019. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 810 | $8.03 | $6,504.30 |
DisclosureSEC source: 0001209191-19-015939 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,197 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001209191-19-015939 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-27 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015939 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,007 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:30 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,821 | $7.74 | $29,561.55 |
DisclosureSEC source: 0001209191-19-008679 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,007 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $8.1377, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 15, 2018 Filed Aug 18, 2018 00:22 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 17,200 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001209191-18-047543 · doc4.xml · derivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,200 Underlying: Common Stock · 17,200 shares Expires 2028-08-14 F2 · derivative.exercise_date: 1/3rd of the total number of shares underlying this option shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. Read SEC document |
| August 15, 2018 Filed Aug 18, 2018 00:22 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 25,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047543 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,828 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest as follows: 1/3rd of the total number of shares shall vest on each of February 5, 2019, August 5, 2019 and February 5, 2020. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-18-019253 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,331 Underlying: Common Stock · 3,500 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,500 | $21.29 | $74,499.95 |
DisclosureSEC source: 0001209191-18-019253 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,028 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 20:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,500 | $4.21 | $14,735.00 |
DisclosureSEC source: 0001209191-18-019253 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,706 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2018. Read SEC document |
| March 02, 2018 Filed Mar 3, 2018 00:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-18-016034 · doc4.xml · derivative · entry 5 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,725 Underlying: Common Stock · 875 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| March 02, 2018 Filed Mar 3, 2018 00:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 875 | $20.00 | $17,500.00 |
DisclosureSEC source: 0001209191-18-016034 · doc4.xml · nonDerivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,322 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| March 02, 2018 Filed Mar 3, 2018 00:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 875 | $1.89 | $1,653.75 |
DisclosureSEC source: 0001209191-18-016034 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantEmployee Stock Option (right to buy) · Derivative | 56,500 | $0.00 Strike: $16.95 | $0.00 |
DisclosureSEC source: 0001209191-18-016034 · doc4.xml · derivative · entry 4 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires 2028-02-27 F3 · derivative.exercise_date: The shares underlying this option shall vest as to 25% after one year following the grant date, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016034 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,322 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-18-003954 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 875 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 875 | $20.00 | $17,500.00 |
DisclosureSEC source: 0001209191-18-003954 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| January 16, 2018 Filed Jan 17, 2018 21:34 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 875 | $1.89 | $1,653.75 |
DisclosureSEC source: 0001209191-18-003954 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 02:13 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-066698 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,475 Underlying: Common Stock · 875 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 02:13 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 875 | $20.00 | $17,500.00 |
DisclosureSEC source: 0001209191-17-066698 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 02:13 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 875 | $1.89 | $1,653.75 |
DisclosureSEC source: 0001209191-17-066698 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 23:56 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 875 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-063316 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 875 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 23:56 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 875 | $20.00 | $17,500.00 |
DisclosureSEC source: 0001209191-17-063316 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| November 30, 2017 Filed Dec 1, 2017 23:56 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 875 | $1.89 | $1,653.75 |
DisclosureSEC source: 0001209191-17-063316 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,697 Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · derivative · entry 6 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,225 Underlying: Common Stock · 3,500 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · derivative · entry 5 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,831 Underlying: Common Stock · 3,500 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,500 | $16.97 | $59,380.65 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · nonDerivative · entry 4 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,500 | $1.89 | $6,615.00 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · nonDerivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 3,500 | $16.97 | $59,380.65 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · nonDerivative · entry 2 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,822 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2017. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 00:14 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 3,500 | $4.21 | $14,735.00 |
DisclosureSEC source: 0001209191-17-061002 · doc4.xml · nonDerivative · entry 1 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,822 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 8, 2017. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 23:48 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-17-050652 · doc4.xml · derivative · entry 3 Liu David Y · CIK 0001675881 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,331 Underlying: Common Stock · 3,500 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests over a four-year period, with 1/48th of the shares subject to the option vesting on the last day of each month following the vesting commencement date, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.